Welcome to our home for news – the latest headlines, all in one place. Click through to view a selection of our media coverage, industry news, videos and more.
Two US lawmakers have introduced a bipartisan bill to create a new payment model to encourage drug developers to develop new classes of antibiotics.
It’s called the PASTEUR Act, which will facilitate upfront payments to companies in exchange for unlimited access to their antibiotics. In turn, drug makers can recover their costs and turn a profit, before selling large volumes of product.
Relevant extracts include:
An antimicrobial drug developer can apply to receive a ‘critical need antimicrobial’ designation
Contracts will range from $750 million to $3 billion and will be paid out over a period of up to 10 years or through the length of patent exclusivity
Botanix Pharmaceuticals wholeheartedly welcomes this news. As we enter a critical period of R&D for our BTX 1801 antimicrobial resistance (AMR) platform, this is a significant endorsement of the immediate need for novel antibiotics and further evidence of the world’s most powerful pharmaceutical influencers prioritising expedited and significant expenditure in this space.
Botanix Pharmaceuticals Executive Director, Matt Callahan, spoke with Stockhead about the global threat of antimicrobial resistance yesterday:
“The alarm bells have been going off the last five years (on antimicrobial resistance), but no one’s really believed that the global economy could be stopped and millions and millions of deaths could be caused by some kind of pathogen – but of course I think we all believe that now, sadly,” he said.
https://botanixpharma.com/wp-content/uploads/AdobeStock_157172577-scaled.jpeg17062560Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2020-09-25 03:42:532023-03-13 21:17:07This new antimicrobial resistance network could boost Recce, Botanix and Next Science
Botanix welcomes, wholeheartedly, today’s news from MTPConnect announcing the formation of an Australian-first network to address the impact of antimicrobial resistance (AMR) on human health.
Professor Geoffrey Coombs, member of the AAMRNet Steering Committee and President of the Australian Society for Antimicrobials, is involved in our BTX 1801 clinical study in Perth. We are fortunate to be collaborating with leaders in this sector to examine the full potential of our platform AMR product.
Addressing the impact of AMR is a foremost priority for our business. We look forward to supporting this network and contributing valuable clinical data to our combined efforts to address what is one of the most significant, pressing threats to global health.
https://botanixpharma.com/wp-content/uploads/Screen-Shot-2020-09-24-at-11.06.34-am.png13602026Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2020-09-24 01:09:242023-03-13 21:17:07Australia’s first Antimicrobial Resistance Network forms to combat global health threat
The emergence of antimicrobial resistance (AMR), including drug-resistant bacteria, or “superbugs”, pose far greater risks to human health than Covid-19, threatening to put modern medicine “back into the dark ages”, an Australian scientist has warned, ahead of a three-year study into drug-resistant bacteria in Fiji.
“If you thought Covid was bad, you don’t want anti-microbial resistance,” Dr Paul De Barro, biosecurity research director at Australia’s national science agency, the CSIRO, told The Guardian.
https://botanixpharma.com/wp-content/uploads/Screen-Shot-2020-09-15-at-1.42.08-pm.png7381236Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2020-09-15 03:43:012023-03-13 21:17:07‘Superbugs’ a far greater risk than Covid in the Pacific, scientist warns
Experts have warned that the COVID-19 pandemic might just be one in a series of increasingly frequent viral outbreaks, as the human species enters what they describe as “a pandemic era”.
Anthony Fauci, leading US immunologist and director of the National Institute of Allergy and Infectious Diseases (NIAID), and David Morens, a medical epidemiologist at NIAID, predict that widespread outbreaks of diseases and epidemics will only accelerate over the coming years as populations grow, societies expand and deforestation increases.
https://botanixpharma.com/wp-content/uploads/Screen-Shot-2020-09-09-at-6.19.58-pm.png7181278Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2020-09-09 08:21:452023-03-13 21:17:07Experts Say Humans Are Living in an ‘Age of Pandemics’—and COVID Won’t Be the Last
‘After colonising the skin explants with methicillin-resistant staphylococcus aureus (MRSA), the “Human Skin Study” found that BTX 1801 successfully eliminated the so-called superbug within 24 hours.’
https://botanixpharma.com/wp-content/uploads/Botanix-Stockhead.png7201280Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2020-09-08 01:35:002023-03-13 21:17:07Botanix makes progress on cannabinoid antimicrobial gel
The PASTEUR Act
/in Featured, Latest News, News /by Haley ChartresTwo US lawmakers have introduced a bipartisan bill to create a new payment model to encourage drug developers to develop new classes of antibiotics.
It’s called the PASTEUR Act, which will facilitate upfront payments to companies in exchange for unlimited access to their antibiotics. In turn, drug makers can recover their costs and turn a profit, before selling large volumes of product.
Relevant extracts include:
Botanix Pharmaceuticals wholeheartedly welcomes this news. As we enter a critical period of R&D for our BTX 1801 antimicrobial resistance (AMR) platform, this is a significant endorsement of the immediate need for novel antibiotics and further evidence of the world’s most powerful pharmaceutical influencers prioritising expedited and significant expenditure in this space.
Read a summary of the bill here.
This new antimicrobial resistance network could boost Recce, Botanix and Next Science
/in Featured, Latest News, News /by Haley ChartresBotanix Pharmaceuticals Executive Director, Matt Callahan, spoke with Stockhead about the global threat of antimicrobial resistance yesterday:
“The alarm bells have been going off the last five years (on antimicrobial resistance), but no one’s really believed that the global economy could be stopped and millions and millions of deaths could be caused by some kind of pathogen – but of course I think we all believe that now, sadly,” he said.
Read the full article here.
Australia’s first Antimicrobial Resistance Network forms to combat global health threat
/in Featured, Latest News, News /by Haley ChartresBotanix welcomes, wholeheartedly, today’s news from MTPConnect announcing the formation of an Australian-first network to address the impact of antimicrobial resistance (AMR) on human health.
The Australian Antimicrobial Resistance network – AAMRNet – was launched in response to urgent recommendations in a new report by MTPConnect, ‘Fighting Superbugs: A Report on the Inaugural Meeting of Australia’s Antimicrobial Resistance Stakeholders’.
Professor Geoffrey Coombs, member of the AAMRNet Steering Committee and President of the Australian Society for Antimicrobials, is involved in our BTX 1801 clinical study in Perth. We are fortunate to be collaborating with leaders in this sector to examine the full potential of our platform AMR product.
Addressing the impact of AMR is a foremost priority for our business. We look forward to supporting this network and contributing valuable clinical data to our combined efforts to address what is one of the most significant, pressing threats to global health.
Read more from MTPConnect here.
‘Superbugs’ a far greater risk than Covid in the Pacific, scientist warns
/in Featured, Latest News, News /by Haley ChartresThe emergence of antimicrobial resistance (AMR), including drug-resistant bacteria, or “superbugs”, pose far greater risks to human health than Covid-19, threatening to put modern medicine “back into the dark ages”, an Australian scientist has warned, ahead of a three-year study into drug-resistant bacteria in Fiji.
“If you thought Covid was bad, you don’t want anti-microbial resistance,” Dr Paul De Barro, biosecurity research director at Australia’s national science agency, the CSIRO, told The Guardian.
Read the full article on The Guardian here.
Experts Say Humans Are Living in an ‘Age of Pandemics’—and COVID Won’t Be the Last
/in Featured, Latest News, News /by Haley ChartresExperts have warned that the COVID-19 pandemic might just be one in a series of increasingly frequent viral outbreaks, as the human species enters what they describe as “a pandemic era”.
Anthony Fauci, leading US immunologist and director of the National Institute of Allergy and Infectious Diseases (NIAID), and David Morens, a medical epidemiologist at NIAID, predict that widespread outbreaks of diseases and epidemics will only accelerate over the coming years as populations grow, societies expand and deforestation increases.
Read the full article on Vice here.
Botanix makes progress on cannabinoid antimicrobial gel
/in Latest News, News /by Haley Chartres‘After colonising the skin explants with methicillin-resistant staphylococcus aureus (MRSA), the “Human Skin Study” found that BTX 1801 successfully eliminated the so-called superbug within 24 hours.’
Read the full article on Stockhead here.